BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/9/2026 8:15:12 AM | Browse: 35 | Download: 88
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 122796
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Study
Article Title Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX
Manuscript Source Unsolicited Manuscript
All Author List Yan Wu, Mi-Mi Xu, Guo-Lin Wang, Wen-Di Du and Xin-Hui Su
ORCID
Author(s) ORCID Number
Xin-Hui Su http://orcid.org/0000-0002-4782-3982
Funding Agency and Grant Number
Corresponding Author Xin-Hui Su, Academic Fellow, MD, PhD, Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. suxinhui@zju.edu.cn
Key Words Gastric cancer; Peripheral blood; Neoadjuvant therapy; Immunotherapy; Sintilimab; Gastric signet ring cell carcinoma; Gastric carcinoma subtypes
Core Tip This study investigated the changes in peripheral blood inflammatory markers and T-cell subsets in patients with gastric cancer at baseline and after neoadjuvant chemotherapy with sintilimab combined with XELOX. Results indicate that high post-treatment monocyte-to-lymphocyte ratio levels are associated with a favorable treatment response, a greater relative change in the proportion of CD8+ T cells may be associated with better prognosis, and diffuse-type gastric cancer may be associated with poorer clinical outcomes. These easily detectable biomarkers offer a new perspective for predicting treatment response and assessing prognosis; however, further validation is required.
Publish Date 2026-10-09 08:15
Citation

Wu Y, Xu MM, Wang GL, Du WD, Su XH. Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX. World J Gastrointest Oncol 2026; 18(10): 122796

URL https://www.wjgnet.com/1948-5204/full/v18/i10/122796.htm
DOI https://doi.org/10.4251/wjgo.122796
Full Article (PDF) WJGO-18-122796-with-cover.pdf